Document is current
Any future updates will be listed below
-
Authors
Bonnin, Elisa https://orcid.org/0009-0005-6544-2736
Rodrigo Riestra, Maria
Marziali, Federico
Mena Osuna, Rafael
Denizeau, Jordan
Maurin, Mathieu
Saez, Juan Jose https://orcid.org/0000-0001-6708-6724
Jouve, Mabel
Bonté, Pierre-Emmanuel https://orcid.org/0000-0002-9732-5826
Richer, Wilfrid
Nevo, Fabien
Lemoine, Sebastien
Girard, Nicolas
Lefevre, Marine
Borcoman, Edith
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Baulande, Sylvain https://orcid.org/0000-0003-3104-1684
Moreau, Helene D.
Sedlik, Christine
Hivroz, Claire https://orcid.org/0000-0002-6794-2890
Lennon-Duménil, Ana-Maria
Tosello Boari, Jimena https://orcid.org/0000-0003-1563-4420
Piaggio, Eliane https://orcid.org/0000-0002-2455-8442
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-IDEX-0001-02 PSL, ANR-11-LABX-0043)
- License Information
-
More Information
Article History
Received: 28 March 2023
Accepted: 17 April 2024
First Online: 3 May 2024
Competing interests
: E.P. is co-founder and consultant for Egle Therapeutics and is share-holders at Mnemo Therapeutics. F.N. and S.L. are employees of Egle Therapeutics. J.T.B. is consultant for Egle Therapeutics. P.E.B. is consultant for Mnemo Therapeutics. The remaining authors declare no competing interests.
